BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, May 29, 2024
Breaking News: Try BioWorld for free for two weeks
See today's BioWorld Science
Home
» GB01-VA-PL2202, a Claudin-6-targeting ADC with potent antitumor efficacy and bystander killing activity
To read the full story,
subscribe
or
sign in
.
Immuno-oncology
GB01-VA-PL2202, a Claudin-6-targeting ADC with potent antitumor efficacy and bystander killing activity
May 7, 2024
No Comments
Researchers from ADC Therapeutics SA presented the discovery and preclinical evaluation of a novel camptothecin-based Claudin-6-specific antibody-drug conjugate (ADC), GB01-VA-PL2202.
BioWorld Science
Conferences
New compound
American Association for Cancer Research
Cancer
Antibody-drug conjugate
Immuno-oncology